HERBAL MANAGEMENT OF LYMPHOMA CASE REPORT
Abstract
Angiocentric lymphoma has currently been recognized as a distinct clinical entity which is the prototype of the putative NK cell lymphomas. A 16- year-old Japanese girl with advanced CD56+ angiocentric lymphoma received high-dose chemotherapy supported with syngeneic peripheral blood stem cell transplantation (PBSCT). Prior to syngeneic PBSCT, she received six cycles of conventional chemotherapy before transplantation, resulting in a partial response. PBSC were mobilized with granulocyte colony-stimulating factor (G-CSF) and collected from her identical twin. High-dose cyclophosphamide, MCNU, etoposide, and carboplatin were used for pretransplant conditioning. Syngeneic PBSCT was well tolerated. She achieved complete remission and is now surviving in continuous complete remission for more than 30 months after syngeneic PBSCT. Thus, marrow-ablative chemotherapy facilitated by autologous or allogeneic PBSCT should be considered as part of the primary therapy for poor prognosis NK cell lymphomasReferences
Cheung MMC, Chan JKC, Lau WH et al. Primary non-Hodgkin’s
lymphoma of the nose and nasapharynx: clinical features,
tumor immunophenotype, and treatment outcome in 113
patients. J Clin Oncol 1998; 16: 70–77.
Harris NL, Jaffe ES, Stein H et al. Revised European–American
classification of lymphoid neoplasms: a proposal from
the International Lymphoma Study Group. Blood 1994; 84:
–1392.
Jaffe ES. Classification of natural killer (NK) cell and NKlike
T-cell malignancies. Blood 1996; 87: 1207–1210.
Wong KF, Chan JKC, Ng CS et al. CD56 (NKH1)-positive
hematolymphoid malignancies: an aggressive neoplasm featuring
frequent cutaneous/mucosal involvement, cytoplasmic
azurophilic granules and angiocentricity. Hum Pathol 1992;
: 798–804.
Emile JF, Boulland ML, Haioun C et al. CD5-CD56+ T-cell
receptor silent peripheral T-cell lymphomas are natural killer
cell lymphomas. Blood 1996; 87: 1466–1473.
Chan JKC, Sin VC, Wong KF et al. Nonnasal lymphoma
expressing the natural killer cell marker CD56: a clinicopathologic
study of 49 cases of an uncommon aggressive neoplasm.
Blood 1997; 89: 4501–4513.
Liang R, Todd D, Chan TK et al. Treatment outcome and
prognostic factors for primary nasal lymphoma. J Clin Oncol
; 13: 666–670.
Kwong YL, Chan ACL, Liang R et al. CD56+ NK lymphomas:
clinicopathologic features and prognosis. Br J
Haematol 1997; 97: 821–829.
Liang R, Chen F, Lee CK et al. Autologous bone marrow
transplantation for primary nasal T/NK cell lymphoma. Bone
Marrow Transplant 1997; 19: 91–93.
Yano T, Katayama Y, Sunami K et al. G-CSF-induced mobilization
of peripheral blood stem cells for allografting: comparative
study of daily single versus divided dose of G-CSF.
Int J Hematol 1997; 66: 169–178.
Harada M, Nagafuji K, Fujisaki T et al. G-CSF-induced mobilization
of peripheral blood stem cells from healthy adults for
allogeneic transplantation. J Hematother 1996; 5: 63–72.
Yamaguchi M, Kita K, Miwa H et al. Frequent expression of
P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer
; 76: 2351–2356.
Teshima T, Miyaji R, Fukuda M et al. Bone-marrow transplantation
for Epstein–Barr-virus-associated natural killer celllarge
granular lymphocyte leukaemia. Lancet 1996; 347: 112
